Drug Trial Radar · NCT01090037
TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
Last checked: Nov 20, 2026Latest source record: Feb 4, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
892
Actual
Start
Mar 2010
Primary completion
Aug 2014
Study completion Jan 2015
Sponsor
- Lead sponsor
- Toray Industries, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Inc
- First posted
- Mar 19, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease: * To confirm the superiority of TRK-100STP over placebo * To determine the recommended therapeutic dose in the 2 doses of TRK-100STP * To assess the safety of TRK-100STP
Conditions
- Chronic Renal Failure
- Glomerular Disease
- Nephrosclerosis
Interventions
TRK-100STP high doseDrug
TRK-100STP low doseDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Renal composite endpoints [Time to first occurrence of one of the following events:]Time frame: 2-4 year
Locations
7 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Beijing, China
Site not named
Hong Kong, Hong Kong
Site not named
Tokyo, Japan
Site not named
Kuala Lumpur, Malaysia
Site not named
Seoul, South Korea
Site not named
Taipei, Taiwan
Site not named
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.